Microorganisms genetically engineered to have modified N-glycosylation activity
Described herein are methods and genetically engineered cells useful for producing an altered N-glycosylation form of a target molecule. Also described are methods and molecules with altered N-glycosylation useful for treating a variety of disorders such as metabolic disorders.
1. A method of producing an altered N-glycosylation form of a target protein, the method comprising:
providing a Yarrowia lipolytica or an Arxula adeninivorans cell genetically engineered to express a protein that promotes phosphorylation of mannosyl moieties of N-glycans and to comprise a deficiency in Outer CHain elongation (OCH1) activity; and
introducing into the cell a nucleic acid encoding a target protein, wherein the cell produces the target protein in an altered N-glycosylation form relative to the N-glycosylation form of the target protein produced in a corresponding non-genetically engineered cell, and
wherein the protein that promotes phosphorylation of mannosyl moieties is:
(a)(i) a wild-type MNN4 polypeptide;
(a)(ii) a deletion variant that is the polypeptide of (a)(i) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;
(a)(iii) a deletion variant that is the polypeptide of (a)(i) or the variant of (a)(ii) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (a)(i) or the variant of (a)(ii); or
(a)(iv) a substitution variant that is the polypeptide of (a)(i), the variant of (a)(ii), or the variant of (a)(iii), but with no more than 10 conservative substitutions,
wherein the variants of (a)(ii), (a)(iii) and (a)(iv) have at least 25% of the phosphorylation-promoting activity of the polypeptide of (a)(i),
(b)(i) a wild-type PNO1 polypeptide;
(b)(ii) a deletion variant that is the polypeptide of (b)(i) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;
(b)(iii) a deletion variant that is the polypeptide of (b)(i) or the variant of (b)(ii) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (b)(i) or the variant of (b)(ii); or
(b)(iv) a substitution variant that is the polypeptide of (b)(i), the deletion variant of (b)(ii), or the deletion variant of (b)(iii), but with no more than 10 conservative substitutions,
wherein the variants of (b)(ii), (b)(iii), and (b)(iv) have at least 25% of the phosphorylation-promoting activity of the polypeptide of (b)(i), or
(c) a wild-type MNN6 polypeptide.
2. The method of claim 1 , further comprising isolating the altered N-glycosylation form of the target protein.
3. The method of claim 1 , wherein the target protein is an exogenous protein.
4. The method of claim 1 , wherein the target protein is an endogenous protein.
5. The method of claim 1 , wherein the target protein is a human protein.
6. The method of claim 1 , wherein the target protein is a pathogen protein, a lysosomal protein, a growth factor, a cytokine, a chemokine, or a fusion protein.
7. The method of claim 1 , wherein the target protein is a protein associated with a lysosomal storage disorder (LSD).
8. The method of claim 7 , wherein the lysosomal storage disorder is Gaucher disease, Tay-Sachs disease, Pompe disease, Niemann-Pick disease, or Fabry disease.
9. The method of claims 7 , wherein the target protein is glucocerebrosidase or galactocerebrosidase.
10. The method of claim 7 , wherein the target protein is selected from the group consisting of alpha-L-iduronidase, beta-D-galactosidase, beta-glucosidase, beta-hexosaminidase, beta-D-mannosidase, alpha-L-fucosidase, arylsulfatase B, arylsulfatase A, alpha-N-acteylgalactosaminidase, aspartylglucosaminidase, iduronate-2-sulfatase, alpha-glucosaminide-N-acetyltransferase, beta-D-glucoronidase, hyaluronidase, alpha-L-mannosidase, alpha- neuraminidase, phosphotransferase, acid lipase, acid ceramidase, sphinogmyelinase, thioesterase, cathepsin K, and lipoprotein lipase.
11. The method of claim 7 , wherein the target protein is human alpha-galactosidase A.
12. The method of claim 1 , wherein the altered N-glycosylation form comprises one or more N-glycan structures selected from group consisting of Mans 5 G1cNAc 2 , Man 8 G1cNAc 2 , and Man 9 G1cNAc 2 .
13. The method of claim 1 , wherein the altered glycosylation is Mans 5 G1cNAc 2 , Man 8 G1cNAc 2 , Man 9 G1cNAc 2 .
14. The method of claim 1 , wherein the cell further comprises a nucleic acid encoding an alpha-mannosidase.
15. The method of claim 14 , wherein the alpha-mannosidase is an alpha 1,2mannosidase.
16. The method of claim 14 , wherein the alpha-mannosidase is mannosidase 1 (MNS1).
17. The method of claim 14 , wherein the alpha-mannosidase is targeted to the endoplasmic reticulum.
18. The method of claim 17 , wherein the alpha-mannosidase is a fusion protein comprising an alpha-mannosidase polypeptide and an HDEL endoplasmic reticulum retention peptide.
19. The method of claim 1 , further comprising additional processing of the glycoprotein.
20. The method of claim 19 , wherein the additional processing comprises enzymatic or chemical treatment of the altered N-glycosylation form of the target protein.
21. An isolated Yarrowia lipolytica or Arxula adeninivorans cell genetically engineered to express a protein that promotes phosphorylation of mannosyl moieties of N-glycans and to comprise a deficiency in Outer CHain elongation (OCH1) activity,.
wherein the protein that promotes phosphorylation of mannosyl moieties is:
(a)(i) a wild-type MNN4 polypeptide;
(a)(ii) a deletion variant that is the polypeptide of (a)(i) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;
(a)(iii) a deletion variant that is the polypeptide of (a)(i) or the variant of (a)(ii) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (a)(i) or the variant of (a)(ii); or
(a)(iv) a substitution variant that is the polypeptide of (a)(i), the variant of (a)(ii), or the variant of (a)(iii), but with no more than 10 conservative substitutions,
wherein the variants of (a)(ii), (a)(iii) and (a)(iv) have at least 25% of the phosphorylation-promoting activity of the polypeptide of (a)(i),
(b)(i) a wild-type PNO1polypeptide;
(b)(ii) a deletion variant that is the polypeptide of (b)(i) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;
(b)(iii) a deletion variant that is the polypeptide of (b)(i) or the variant of (b)(ii) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (b)(i) or the variant of (b)(ii); or
(b)(iv) a substitution variant that is the polypeptide of (b)(i), the deletion variant of (b)(ii), or the deletion variant of (b)(iii), but with no more than 10 conservative substitutions,
wherein the variants of (b)(ii), (b)(iii), and (b)(iv) have at least 25% of the phosphorylation-promoting activity of the polypeptide of (b)(i), or
(c) a wild-type MNN6 polypeptide.
22. The cell of claim 21 , said cell further comprising a nucleic acid encoding a target protein, wherein the cell produces the target protein in an altered N-glycosylation form relative to the N-glycosylation form of the target protein produced in a corresponding non-genetically engineered cell.
23. The cell of claim 21 , said cell further comprising a nucleic acid encoding an alpha-mannosidase.
24. A method of producing an altered N-glycosylation form of a target protein, the method comprising contacting a target protein with a cell lysate prepared from a Yarrowia lipolytica or an Arxula adeninivorans cell genetically engineered to express a protein that promotes phosphorylation of mannosyl moieties of N-glycans and to comprise a deficiency in Outer CHain elongation (OCH1) activity,
wherein the contacting of the target protein with the cell lysate results in an altered N-glycosylation form of the target protein relative to the N-glycosylation form of the target protein produced from the cell lysate of a corresponding non-genetically engineered cell, and
wherein the protein that promotes phosphorylation of mannosyl moieties is:
(a)(i) a wild-type MNN4 polypeptide;
(a)(ii) a deletion variant that is the polypeptide of (a)(i) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;
(a)(iii) a deletion variant that is the polypeptide of (a)(i) or the variant of (a)(ii) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (a)(i) or the variant of (a)(ii); or
(a)(iv) a substitution variant that is the polypeptide of (a)(i), the variant of (a)(ii), or the variant of (a)(iii), but with no more than 10 conservative substitutions,
wherein the variants of (a)(ii), (a)(iii) and (a)(iv) have at least 25% of the phosphorylation-promoting activity of the polypeptide of (a)(i),
(b)(i) a wild-type PNO1 polypeptide;
(b)(ii) a deletion variant that is the polypeptide of (b)(i) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;
(b)(iii) a deletion variant that is the polypeptide of (b)(i) or the variant of (b)(ii) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (b)(i) or the variant of (b)(ii); or
(b)(iv) a substitution variant that is the polypeptide of (b)(i), the deletion variant of (b)(ii), or the deletion variant of (b)(iii), but with no more than 10 conservative substitutions,
wherein the variants of (b)(ii), (b)(iii), and (b)(iv) have at least 25% of the phosphorylation-promoting activity of the polypeptide of (b)(i), or
(c) a wild-type MNN6 polypeptide.
25. The method of claim 24 , wherein the cell further comprises a nucleic acid encoding an alpha-mannosidase.
26. A substantially pure culture of Yarrowia lipolytica or Arxula adeninivorans cells, a substantial number of which are genetically engineered to express a protein that promotes phosphorylation of mannosyl moieties of N-glycans and to comprise a deficiency in Outer CHain elongation (OCH1) activity, and
wherein the protein that promotes phosphorylation of mannosyl moieties is:
(a)(i) a wild-type MNN4 polypeptide;
(a)(ii) a deletion variant that is the polypeptide of (a)(i) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;
(a)(iii) a deletion variant that is the polypeptide of (a)(i) or the variant of (a)(ii) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (a)(i) or the variant of (a)(ii); or
(a)(iv) a substitution variant that is the polypeptide of (a)(i), the variant of (a)(ii), or the variant of (a)(iii), but with no more than 10 conservative substitutions,
wherein the variants of (a)(ii), (a)(iii) and (a)(iv) have at least 25% of the phosphorylation-promoting activity of the polypeptide of (a)(i),
(b)(i) a wild-type PNO1 polypeptide;
(b)(ii) a deletion variant that is the polypeptide of (b)(i) but lacks up to twenty amino acid segments, each segment consisting of two amino acids;
(b)(iii) a deletion variant that is the polypeptide of (b)(i) or the variant of (b)(ii) but lacks up to twenty single, non-contiguous amino acids of the polypeptide of (b)(i) or the variant of (b)(ii); or
(b)(iv) a substitution variant that is the polypeptide of (b)(i), the deletion variant of (b)(ii), or the deletion variant of (b)(iii), but with no more than 10 conservative substitutions,
wherein the variants of (b)(ii), (b)(iii), and (b)(iv) have at least 25% of the phosphorylation-promoting activity of the polypeptide of (b)(i), or
(c) a wild-type MNN6 polypeptide.
27. The substantially pure culture of claim 26 , said cells further comprising a nucleic acid encoding a target protein, wherein the cell produces the target protein in an altered N-glycosylation form relative to the N-glycosylation form of the target protein produced in a corresponding non-genetically engineered cell.
28. The substantially pure culture of claim 26 , said cell further comprising a nucleic acid encoding an alpha-mannosidase.